BWBei Wang

Bei Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bei Wang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Shengkai Zuo

    Department of Biopharmaceutics, Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Pharmacy, Tianjin Medical University, Tianjin, China

    3 shared publications
  • Jiao Liu

    Department of Pharmacology, Tianjin Key Laboratory of Inflammatory Biology, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Experimental Hematology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China

    2 shared publications
  • Jinying Zhang

    Department of Cardiology, First Affiliated Hospital of Zhengzhou University, China

    2 shared publications
  • Yuxuan Jin

    Department of Cardiology, First Affiliated Hospital of Zhengzhou University, China (J.L., Y.J., J.Z., Y.Y.).

    2 shared publications
  • Chenghao Xuan

    The Province and Ministry Co‐Sponsored Collaborative Innovation Center for Medical Epigenetics State Key Laboratory of Experimental Hematology Key Laboratory of Breast Cancer Prevention and Therapy (Tianjin Medical University) Ministry of Education Key Laboratory of Immune Microenvironment and Disease (Tianjin Medical University) Ministry of Education Department of Biochemistry and Molecular Biology School of Basic Medical Sciences Tianjin Medical University Tianjin China

    1 shared publication
  • Chengsen Mu

    Department of Pharmacology and Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University, China. (J.L., S.Z., C.M., B.W., D.H., Q.L., Y.Y.)

    1 shared publication

Latest Publications

  • Open Access

    BRD4770 protects against DOX-induced cardiotoxicity by inhibiting apoptosis and ferroptosis

    by Jingrong Shao, Rui Xiao, Ting Wang, Fengshuo Wang, Bei Wang, Dongli Zhang, Lulu Wang, Jingchao Li, Jiao Liu, Shengkai Zuo

    Doxorubicin (DOX) is an effective anticancer drug, but its clinical utility is limited mainly by cardiotoxicity causing cardiomyocyte ferroptosis and apoptosis. While DOX-induced cardiotoxicity (DIC) involves epigenetic changes, no systematic epigenetic intervention studies have been reported. Here, we identified BRD4770 as a potential small molecule against DIC through the Epigenetics Compound Library screening. BRD4770 inhibited DOX-induced cardiomyocyte ferroptosis and apoptosis by reducing reactive oxygen species (ROS) production and lipid peroxidation and maintaining glutathione homeostasis. BRD4770 treatment alleviated DIC without affecting the antitumor effects of DOX. Mechanistically, BRD4770 promoted nuclear factor erythroid 2-related factor 2 (Nrf2)/activating transcription factor 4 (ATF4)–solute carrier family 7 member 11 (SLC7A11) signaling and suppressed DOX-induced cardiomyocyte death by reducing methylation of lysine 9 on histone 3. Last, we constructed a ROS-responsive nanoliposome loaded with BRD4770 and conjugated with the cardiac-targeting peptide for primary cardiomyocyte, which provided better protection against DIC. These findings suggest that BRD4770 has the potential to prevent cardiomyocyte death–related cardiomyopathy.


  • Dot1L Promotes Stress-Induced Cardiac Hypertrophy in Mice via Tbx6

    by Jiao Liu, Yuxuan Jin, Shengkai Zuo, Chengsen Mu, Bei Wang, Dandan Huang, Qian Liu, Kai Zhang, Jiangping Song, Chenghao Xuan, et al.

    BACKGROUND: Sustained pathological cardiac hypertrophy eventually leads to heart failure; however, there is currently no effective therapeutic approach. Epigenetic dysregulation, including histone modification alterations, is implicated in cardiac hypertrophy development. Yet, the detailed mechanisms are not completely elucidated. METHODS: Nano-HPLC-MS/ms was conducted to analyze histone modifications. Cardiomyocyte-specific Dot1L (disruptor of telomeric silencing 1-like) knockout and transgenic mice were generated to evaluate the function of Dot1L in cardiac hypertrophy. Stress was induced in mice by transverse aortic constriction or continuous isoproterenol infusion. RNA-sequencing and chromatin immunoprecipitation sequencing were combined and analyzed to identify the direct transcriptional target of Dot1L, which was verified by multiple molecular biological methodologies. Primary neonatal rat ventricle myocytes were used to identify potential targets and study the molecular mechanisms. RESULTS: Histone H3K79 dimethylation and its specific methyltransferase Dot1L were upregulated in hypertrophic stimuli-treated cardiomyocytes, cardiac tissues from pressure overload–stressed mice, and patients with hypertrophic cardiomyopathy. The ablation of Dot1L in cardiomyocytes of adult mice protected against pressure overload–induced hypertrophy. Chromatin immunoprecipitation sequencing assay and genome-wide transcriptional analysis showed that Dot1L-catalyzed H3K79 dimethylation promoted the expression of transcription factor Tbx6 in stressed neonatal rat ventricle myocytes. Knockdown of Tbx6 abolished Dot1L overexpression-exaggerated cardiac hypertrophy in mice in response to pressure overload. The Dot1L inhibitor SGC0946 treatment markedly improved isoproterenol-induced cardiac hypertrophy in mice. CONCLUSIONS: Dot1L–H3K79 dimethylation–Tbx6 axis facilitates pressure overload–induced cardiac hypertrophy. Targeting Dot1L may be a promising therapeutic strategy for heart failure.


  • Open Access

    Ex vivo development, expansion and in vivoanalysis of a novel lineage of dendritic cells from hematopoietic stem cells

    by Shuhong Han, Yichen Wang, Bei Wang, Ekta Patel, Starlyn Okada, Li-Jun Yang, Jan S Moreb, Lung-Ji Chang

    Dendritic cells (DCs) play a key role in innate and adaptive immunity but the access to sufficient amount of DCs for basic and translational research has been limited. We established a novel ex vivo system to develop and expand DCs from hematopoietic stem/progenitor cells (HPCs). Both human and mouse HPCs were expanded first in feeder culture supplemented with c-Kit ligand (KL, stem cell factor, steel factor or CD117 ligand), Flt3 ligand (fms-like tyrosine kinase 3, Flt3L, FL), thrombopoietin (TPO), IL-3, IL-6, and basic fibroblast growth factor (bFGF), and then in a second feeder culture ectopically expressing all above growth factors plus GM-CSF and IL-15. In the dual culture system, CD34+ HPCs differentiated toward DC progenitors (DCPs), which expanded more than five orders of magnitude. The DCPs showed myeloid DC surface phenotype with up-regulation of transcription factors PU.1 and Id2, and DC-related factors homeostatic chemokine ligand 17 (CCL17) and beta-chemokine receptor 6 (CCR6). Multiplex ELISA array and cDNA microarray analyses revealed that the DCPs shared some features of IL-4 and IL-15 DCs but displayed a pronounced proinflammatory phenotype. DCP-derived DCs showed antigen-uptake and immune activation functions analogous to that of the peripheral blood-derived DCs. Furthermore, bone marrow HPC-derived DCP vaccines of tumor-bearing mice suppressed tumor growth in vivo. This novel approach of generating DCP-DCs, which are different from known IL-4 and IL-15 DCs, overcomes both quantitative and qualitative limitations in obtaining functional autologous DCs from a small number of HPCs with great translational potential.